Right Test Selection, Right Clinical Setting: Aligning Fit-for-Purpose, Cost, Feasibility, & Global Deployment in Liquid Biopsies

• Critical Decision-Making Matrix: Balancing clinical utilities, drug development approaches, and risk mitigation in liquid-biopsy assay selection strategy
• Define best practice for enabling liquid biopsy from clinical trials to routine clinical application: analytical performance, cost, reimbursement, tiered cut-off strategy, operations, regulatory end-to-end CDx integration, etc.
• Embracing and Taming AI: Accelerating real-world, multi-variant liquid-biopsy analytics, while recognizing that model complexity can introduce validation, regulatory, or adoption challenges and potentially diminish immediate clinical gain

Speakers:

Zheng Feng

Head, Clinical Genomics, Clinical Measurement Sciences

EMD Serono, An affiliate of Merck KGaA, Darmstadt, Germany